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1. Introduction 
Amyloidosis is uncommon. Data from Olmsted County, Minnesota, report age-adjusted 
incidences between 6.1 and 10.5 per million person-years.1 It is estimated that there are 1275 
to 3200 new cases annually in the United States.1, 2 Amyloidosis is classified by the precursor 
plasma proteins that form the extracellular fibril deposits. The primary systemic type, AL, is 
due to monoclonal immunoglobulin free light chains, the hereditary (“familial”) type is due 
to mutant transthyretin deposition, the wild type transthyretin type (wild type TTR, or 
“senile” type) is due to normal wild-type transthyretin deposition, and the secondary type 
(AA type) is related to amyloid A protein.2, 3 Amyloidosis, especially the AL type, frequently 
involves the heart and can cause arrhythmias, heart failure with left ventricular diastolic 
dysfunction, and sudden cardiac death.4, 5 In part because of cardiac involvement, AL 
amyloidosis has the worst prognosis, with a median survival of 6 months when heart failure 
is present.2, 5-7 Many patients with cardiac amyloidosis die suddenly, presumably related to 
either arrhythmia or electromechanical dissociation.8 However, systematic studies evaluating 
the causes of death are lacking until recently. 
2. Case reports of intracardiac thrombosis in cardiac amyloidosis 
We initially saw a 58-year-old woman with primary amyloidosis who presented with 
biatrial thrombosis while in sinus rhythm. The patient presented with orthopnea, postural 
hypotension, epigastric pain, anorexia, nausea, vomiting, and lower extremity edema that 
had progressed for 5 months. Esophageal gastric endoscopy showed negative findings, but a 
gastric mucosa biopsy specimen was positive for amyloid deposition. Examinations from 
other institution included a transthoracic echocardiogram and a coronary angiogram 1 month 
earlier were unremarkable. She was referred to Mayo Clinic for further evaluation. Physical 
examination findings included a pulse rate of 106 beats per minute, blood pressure of 
114/80 mm Hg, and an elevated jugular venous pressure. Her lungs were clear to auscultation. 
Her heart rate and rhythm were regular and had no appreciable murmur, rub, or gallop. She 
had mild hepatomegaly and moderate bilateral pitting edema in both lower extremities.  
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Immunoglobulin G gama monoclonal protein was detected in her serum and urine. The 
electrocardiogram showed sinus tachycardia and a heart rate of 104 beats per minute, low 
QRS voltage, and a Q wave in V1 through V4. A transthoracic echocardiogram showed a 
large mobile mass (32×17 mm) protruding from the left atrial appendage (Fig. 1) that was 
consistent with a thrombus. Concentric left ventricular wall thickening, right ventricular free 
wall thickening, and the granular “sparkling” appearance of the myocardium was noted. 
The generalized hypokinetic left ventricle had a mildly reduced ejection fraction of 45 %. 
Other characteristic findings of cardiac amyloidosis that also were present included 
thickened cardiac valves and atrial septum, moderately dilated atria, inferior vena cava and 
hepatic vein dilatation with systolic flow reversal, and small circumferential pericardial 
effusion. A restrictive left ventricle filling pattern was apparent and suggested considerably 
elevated left ventricular filling pressure (figure 2). There was minimal atrial reversal in the 
pulmonary vein. Tissue Doppler echocardiography showed only small mitral A waves but 
no A′ waves in the mitral annulus (figure 3). These observations suggested atrial 
electromechanical dissociation, also termed atrial standstill.  
 
 
Fig. 1. A transthoracic echocardiogram of 4 chambers view showed a large mobile mass 
(32×17 mm) protruding from the left atrial appendage that was consistent with a thrombus. 
Concentric left ventricular wall thickening, right ventricular free wall thickening, and the 
granular “sparkling” appearance of the myocardium was noted 
The patient was immediately hospitalized and received anticoagulation therapy with 
intravenous heparin. She quickly became confused and hypotensive, had decompensated 
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Fig. 2. A restrictive left ventricle filling pattern was apparent and suggested considerably 
elevated left ventricular filling pressure 
 
 
Fig. 3. Tissue Doppler echocardiography showed only small mitral A waves but no A′ 
waves in the mitral annulus 
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heart failure and then cardiogenic shock, and required inotropic support. On her third 
hospitalization day, she had a cardiac arrest and could not be resuscitated. 
An autopsy confirmed thrombi in the left atrial appendage (Fig. 4) and right atrial 
appendage, and multiple infarctions were identified in the distal small bowel, ascending 
colon, bilateral kidneys, and spleen. Histologic studies showed extensive amyloid 
deposition in the heart, kidney, spleen, gastrointestinal tract, and pancreas (figure 5 a and b). 
Interestingly, the patient had not reported abdominal pain or other gastrointestinal 
symptoms, which could suggest that a mesenteric embolism occurred before death.  
 
MV
 
Fig. 4. An intracardiac thrombus in the left atrial appendage (LAA); MV: mitral valve 
The mechanism underlying intracardiac thrombosis in sinus rhythm for a patient with 
cardiac amyloidosis was not clear. We postulated that severely reduced atrial contractility 
attributable to amyloid infiltrate, increased left atrial afterload, and left atrial enlargement 
with depressed left ventricle systolic and diastolic function may partially explain why the 
patient developed left atrial thrombosis in sinus rhythm.  
There have been only a few similar case reports in the literature.9-12 These cases shared some 
common salient clinical features. First, all the patients were in normal sinus rhythm, which 
is very rare for intracardiac thrombosis while in sinus rhythm. Second, their LVEF were 
normal or only mild depressed. Third, intracardiac thrombosis was often undiagnosed until 
the index catastrophic pulmonary or systemic embolism. Forth, very poor outcome with 
most patients died with in a few days and few months after the diagnosis. The 
characteristics of these subjects were summarized in the Table 1.  
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(a) 
  
(b) 
Fig. 5. Extensive interstitial amyloid deposition in the heart (figure a), kidney, spleen, 
gastrointestinal tract, and pancreas (figure b). The amyloid was stained as light pink on the 
Congo red stain and as green on sulfated Alcian blue stain 
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Authors  No Presentation Location Rhythm Method Out come 
Botker9 1 46 W, AL, recurrent stroke,  LA SR Autopsy Died 1 m later of 
cardiac/renal failure 
Plehn24 1 58 W; AL, CHF, LVEF 50%.  LAA SR TTE Stroke/Heart Tx 
4mons/died 14 mons 
Browne10 2 66 M, MM, CHF, LVEF 46%, 
RLE embolism  
54 M, AL, nephrotic 
syndrome, CHF, LVEF 57%, 
RLE embolism. 
 
Atria/LV 
 
Unclear 
SR/PVC 
 
SR/PAC
Autopsy 
 
Autopsy 
Deceased in 3 days due 
to CHf/shock SCD 6 
mons later 
Willens15 1 74 W, CHF, LLE embolism. 
Mild LV systolic 
dysfunction.  
L/RAA SR TEE Deceased “several 
mons” later 
Dubrey17 
 
3 44/W; AL, CHF, EF 30% 
52 W; AL, CHF,  
58 W; AL, CHF, LVEF 50% 
L/RAA 
LAA 
LAA 
SR 
SR 
SR 
Autopsy 
TTE 
TTE 
Died of CHF 4 m later 
Died of CHF 1 m later 
Stroke/Heart Tx 4 m 
later /Died 14 m later 
Cools12 1 64 M, MM, sever edema, 
and CHF no nephrotic 
syndrome ?LVEF 
IVC SR CT/US Deceased 4 mons later 
intestine infarction 
Santarone11, 16 3 60 W, AL, CHF, nl LVEF 
62 W, AL, CHF, nl LVEF 
65 M, AL, SOB, nl LVEF 
Atria 
LAA 
LAA 
SR 
SR 
SR/PVC 
TTE/TEE 
TEE 
TTE 
SCD/PE 15 d later 
Died of CHF 9 m later 
SCD 4 m later 
Table 1. Summary of the case report on intracardaic thrombosis and their clinical features in 
cardiac amyloidosis 
3. Intracardiac thrombosis and embolism from autopsy data at the Mayo 
Clinic 
The frequency of intracardiac thrombosis and its relationship to thromboembolic 
complications and mortality had been not well established. To clarify this issue, we 
reviewed autopsy and explanted hearts with various types of amyloidosis to determine how 
frequently intracardiac thrombi are present and how frequently they cause embolic events 
or death. We then elucidated the clinical and echocardiographic characteristics that predict 
intracardiac thrombosis and embolism. We searched the Mayo Clinic Tissue Registry 
database for cases of cardiac amyloidosis from1996 to 2005.13 Of 142 cases, 26 were excluded 
because of inadequate tissue or incomplete clinical information. The remaining 116 cases 
included 112 autopsy cases and 4 surgically explanted hearts. A control group included 46 
non-amyloid fatal trauma cases. 
3.1 Transthoracic echocardiogram 
Transthoracic echocardiograms (TTE) were obtained in 82/116 patients. The TTE was 
reviewed independently without knowledge of the clinical and pathological data. TTE 
parameters extracted included left ventricular (LV) ejection fraction (LVEF), LV end 
diastolic diameter (LVEDD), LV end systolic diameter (LVESD), stroke volume, ventricular 
septum thickness, LV posterior wall thickness, right ventricular (RV) free wall thickness, RV 
systolic pressure, left atrium (LA) volume index, right atrium (RA) enlargement (0=normal, 
1=mild, 2=moderate, 3=severe), LV diastolic function grade,14 mitral inflow E and A 
velocity, deceleration time, mitral septal annulus tissue Doppler velocity (early peak 
diastolic velocity: e’, late peak diastolic velocity: a’) and pulmonary venous flow profile 
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[peak systolic velocity (S), peak diastolic velocity (D), D/S, and atrial contractile velocity], 
E/A, and E/e’.14 HR and BP at the time of TTE were documented. 
3.2 Pathology data 
All cardiac chambers were examined for thrombi. Thrombi were characterized as to their 
exact anatomic location and size. The presence of cardiac amyloid was confirmed with 
Congo red or sulfated Alcian blue stain. Amyloid subtype was determined 
immunohistochemically with antibodies against serum amyloid P component, lambda and 
kappa free immunoglobulin light chains, transthyretin, amyloid A component, and beta-2 
microglobulin.  
3.3 Cause of death 
The autopsy reports were evaluated by a pathologist and a cardiologist without knowledge 
of the patient’s clinical diagnosis (i.e., trauma, amyloidosis, amyloidosis type, or cardiac 
rhythm). Death was due to a thromboembolic cause if: major acute pulmonary emboli were 
present, irrespective of pulmonary infarction; mesenteric artery embolism with bowel 
infarction was present; major embolic stroke with associated intracranial hemorrhage was 
present or if emboli were the cause of complications such as aspiration pneumonia and 
death; renal infarcts were present with renal failure; or death occurred during or shortly 
after surgical intervention for emboli. 
3.4 Results 
Age ranged from 31-101 years (mean of 72±16). Sixty-one percent were men. In the control 
group, mean age was 55±27 years; 69% were men. The demographic data for the amyloid 
patients are shown in Table 2. There were 55 AL cases, 55 wild type TTR cases, 4 AA types, 
and 2 familial types. Because AA and familial types are rare (n = 6), they were combined 
into one group with the TTR cases (called other, n=61). Results were similar with and 
without these. Compared with the other amyloid group, the AL was younger; had less AF; a 
shorter survival time from the onset of symptoms and less commonly had CAD (Table 2). 
They had thicker ventricular architecture. There were no significant difference in CHF 
history in two groups but the AL type had greater value for NYHA class. There were no 
differences in gender, ethnicity, creatine, and LVEF. 
3.4.1 Intracardiac thrombus  
Intracardiac thrombi were identified in 38/116 (33%) hearts. Twenty-three had 1 thrombus 
while 15 had 2-5 thrombi for a total of 63. Thirty-six were in the RA, 19 in the LA (Figure 1), 
4 on the coronary sinus valve, 3 in the RV, and 1 in the LV. No intracardiac thrombus was 
identified in the 46 fatal trauma subjects. There were significant differences in the frequency 
of intracardiac thrombosis between the cardiac amyloid group and the control group (33% 
versus 0%, p<0.0001). The AL group had more intracardiac thrombi than the other amyloid 
group (51% versus 16%, p<0.0001). Of the 4 AA cases, 2 had intracardiac thrombus. There 
were none in the familial cases.  
3.4.2 Embolic events and cause of death 
There were 23 embolic events in patients with amyloid. There were 19 fatal and 4 non-fatal 
emboli. AL patients had more fatal thromboembolism (14/53; 26%) than the other amyloid 
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patients (5/59; 8 %) and than the control group (1/46; 2%; p<0.001). Embolic fatalities for the 
AL group included 7 pulmonary emboli (PE), 1 mesentery artery embolus with bowel 
infarction, 1 iliac artery embolus and the patient died during attempted embolectomy, and 5 
cases with multiple emboli. In addition, there were 4 non-fatal embolic events in the AL 
group including 3 found at autopsy and 1 with PE and brachial artery embolism who 
survived after cardiac transplant. Among the other amyloid group, there were 5 embolic 
fatalities, including 3 PEs, 1 mesenteric artery embolus with bowel infarction, and 1 case 
with multiple systemic emboli. 
 
 AL (n=55) Other Amyloid (n=61) P value 
Age, years 60 ± 11 83 ± 11 <0.0001 
Gender, % male 61 62 =0.80 
Ethnic, % Caucasian  100 100 =0.53 
Atrial fibrillation, % 22 45 =0.008 
Anticoagulation , % 26 37 =0.21 
Survival time (months) 23 ± 25 63 ± 12 =0.01 
CAD by autopsy, % * 10 90 <0.0001 
CAD severity score (0 to 4) * 1.5 (1.2-1.5) 3.3 (2.9-3.5) <0.0001 
Cardiac mass, g 532±150 474±132 =0.017 
LV septal thickness, mm 16.5±4.2 16.0±4.2 =0.26 
LV posterior wall, mm 16.0±3.5 14.7±3.8 =0.029 
RV free wall, mm 6.0±2.4 4.9±1.7 =0.006 
CHF (%) 77 63 =0.10 
NYHA class (1-4) 2.8±1.2 2.1±1.2 =0.01 
LVEF (%) 50 ± 18 52 ± 16 =0.66 
Creatine mg/dL 2.3 ± 1.5 1.8 ± 1.1 =0.07 
CAD = coronary artery disease; CAD severity score at autopsy: 0 = none, 1 = minimal, 2 = mild,  
3 = moderate, 4 = severe. 
Table 2. Patient characteristics in AL and the other amyloid groups 
3.4.3 Clinical characteristics, TTE and thromboembolism  
Forty-five subjects (40%) had intracardiac thrombosis, embolism or both. Compared to the 
group without thromboembolism, they were younger, less often hypertensive, had more AL 
type, and lower systolic BP (Table 3). The thromboembolic group had less CAD and when 
present, less extensive involvement. Other demographic and clinical variables were similar.  
TTE features are in Table 3. Times from TTE to death were similar. The thromboembolic 
group had a higher HR at TTE, a smaller LVEDD, thicker LV posterior and RV walls, a 
smaller SV, a lower RV systolic pressure, a lower LVEF, worse LV diastolic function, a shorter 
deceleration time, poorer LA mechanical activity (a lower A and a’ velocity), and a higher 
E/A and E/e’ than the non thromboembolic group. Furthermore, PV peak systolic velocity 
and A velocity were significantly lower and D/S was higher. LA volume index and RA size 
were not different (Table 4). RV wall was thicker in subjects who had RA thrombosis 
compared with those who did not have RA thrombosis (7.9±2.7 mm vs. 6.6±3.1 mm, p=0.02).  
3.4.4 Multivariate analysis and ROC 
By multivariate analysis, AL type [OR=15.6 (2.8-117.6), p=0.001] and AF [OR=6.0 (1.7-26.7), 
p=0.004] were independently associated with thromboembolism in a model with clinical 
variables (Table 5) with high odds ratios for both [OR=55.0 (8.1-1131.5), p<0.0001]. For TTE 
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variables, RV wall thickness [OR=1.3 (1.0-1.7), p=0.03] with 1 mm increase in the wall, LV 
diastolic function [OR 8.8 (1.6-64.1), p=0.01] with restrictive pattern (grade 3 or 4) compared 
with grade 2 or less, and HR at echo [OR=1.7 (1.1-2.9), p=0.02] with 10 beats/minute of 
increase were independently associated with thromboembolism. There were no differences 
in thromboembolic risk between LV diastolic function grade 2 versus grade 1 or normal 
diastolic function. When both clinical and TTE variables were included in the analyses, AL 
type [OR 8.4 (1.8-51.2), p=0.006], LV diastolic function [OR=12.2 (2.7-72.7), p=0.0008] and a 
higher HR [OR=1.1 (1.0-1.2), p=0.048] were independently associated with thromboembolism 
(Table 5). Other variables were not associated with thromboembolism including atrial sizes. 
The receiver operating characteristic curve (ROC) for using LV diastolic function grade to 
predict thromboembolism is shown in Figure 2. Grade 3 LV diastolic dysfunction had a 
sensitivity of 78% and a specificity of 79%. The area under curve was 0.81. Using amyloid 
type, LV diastolic function, and HR, the area under the curve was 0.87. Presence of both LV 
diastolic grade 3 or 4 and AL type increased specificity to 94 % but decreased sensitivity to 
56 % as one would expect.  
 
 With (n=45) Without (n=71) P value 
Age, years 65 ± 2.2 77 ± 1.8 <0.0001 
Gender, % male 58 62 0.67 
Body mass index, kg/m2 26.0±0.9 26.7±0.8 0.54 
Hypertension, % 17 41 0.008 
Diabetes, % 7 19 0.08 
CHF, % 65 71 0.55 
NYHA class (1-4) 2.4±1.3 2.3±1.2 0.65 
Atrial fibrillation, % 37 33 0.64 
Anticoagulation , % 36 28 0.42 
Cancer, % 15 22 0.41 
Syncope, % 34 17 0.08 
AL amyloidosis, %  73 31 <0.0001 
Stem cell transplant, % 23 10 0.09 
Recent operation, % 10 17 0.31 
History of thrombosis, % 27 24 0.76 
Systolic BP, mm Hg 111±18 128±24 0.0005 
Diastolic BP, mm Hg 67±12 69±15 0.54 
Creatinine, mg/dL 2.2±1.7 1.9±1.1 0.17 
CAD by autopsy, %  29.3 55.4 0.008 
CAD severity score (0 to 4) * 2.0±1.2 2.7±1.3 0.02 
* CAD severity score: 0 = no, 1 = minimal, 2 = mild, 3 = moderate and 4 = severe.  
Table 3. Characteristics in patients with and without Thromboembolism 
3.5 Discussion 
The Mayo autopsy study of patients with cardiac amyloidosis identifies a high frequency of 
intracardiac thrombosis, especially in AL patients, despite normal sinus rhythm and 
relatively preserved LVEF. Most thrombi arose in the atria. Thrombosis and embolism 
caused significant fatality. AL type, AF, poor LV diastolic function, RV wall thickness by 
TTE, and higher HR were independent predictors for thromboembolism. Many risk factors  
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 With (n=35) Without (n=47) P Value 
Time (from TTE to death), day 15 (1-55) 43 (2-209) 0.12 
HR at echo, beats/min 86±17 79±14 0.02 
LV end diastolic diameter, mm 44.3±7.8 48.1±8.1 0.04 
LV end systolic diameter, mm 32.4±9.3 33.1±9.8 0.76 
LV septal thickness, mm 14.2±3.9 12.9±3.3 0.12 
LV posterior wall thickness, mm 13.8±3.6 12.2±3.1 0.03 
RV free wall thickness, mm 8.3±3.6 5.9±2.1 0.0007 
LA volume index (cc/m2) 40.1±14.9 48.2±35.2 0.21 
RA enlargement (0-3) 1.8±1.2 1.4±1.1 0.08 
Stroke volume, mL 51.1±20.9 67.6±23.4 0.002 
RV systolic pressure, mm Hg 44.3±9.4 51.1±15.9 0.045 
LVEF (%) 46±19 54±15 0.03 
LV diastolic function grade (0-4) 3.1±1.1 1.9±0.8 0.0001 
Mitral deceleration time (ms) 160±37 193±60 0.006 
Mitral E velocity (m/s) 0.87±0.21 0.90±0.26 0.65 
Mitral A velocity (m/s) 0.27±0.29 0.52±0.33 0.0008 
E/A 3.4±2.6 2.0±1.9 0.03 
Mitral annulus e’ velocity (cm/s) 4.4±2.3 5.9±2.7 0.06 
Mitral annulus a’ velocity (cm/s) 2.3±3.3 6.6±4.7 0.003 
E/e’ 23±12 16±8 0.02 
PV systolic velocity, m/s 0.32±0.18 0.48±0.20 0.002 
PV diastolic velocity, m/s 0.65±0.20 0.60±0.18 0.37 
PV A velocity, m/s 0.14±0.13 0.24±0.13 0.008 
PV diastolic/systolic ratio 3.0±2.3 1.5±0.8 0.001 
Table 4. TTE characteristics in subjects with and without Thromboembolism 
 
Dependent Variate Models * Predictors OR 95 % CI P value 
Thromboembolism Model 1 AL type 15.6 2.8-117.6 0.001 
  AF 6.0 1.7-26.7 0.004 
  AL and AF 55.0 8.1-1131.5 0.0001 
Thromboembolism Model 2 RV free wall 1.3 1.0-1.7 0.03 
  LV diastolic function 8.8 1.6-64.1 0.01 
  Heart rate 1.7 1.1-2.9 0.02 
Thromboembolism Model 3 AL type 8.4 1.8-51.2 0.006 
  LV diastolic function 12.2 2.7-72.7 0.0008 
  Heart rate 1.1 1.0-1.2 0.048 
CI = confidence interval. 
* Model 1: Clinical variates included are age, amyloid type, AF, hypertension, and CAD. 
Model 2: Echo variates included are RV wall thickness, LV diastolic function, LVEF, SV, mitral A 
velocity, and HR at TTE.  
Model 3: Combined model with variates included amyloid type, AF, RV free wall, LV diastolic function, 
SV, and HR.  
Table 5. Predictors for thromboembolism by multivariate analyses 
www.intechopen.com
Intracardiac Thrombosis, Embolism and Anticoagulation  
Therapy in Patients with Cardiac Amyloidosis – Inspiration from a Case Observation 
 
39 
in patients without amyloidosis such as age, CHF, hypertension and diabetes were not 
significantly associated with thromboembolism from the Mayo Autopsy study. Surprisingly, 
atrial size was not associated with thromboembolism despite the fact that most thrombi 
were found in the atria. Measures of atrial mechanical activity such as A velocity and a’ 
velocity were different only in univariate analyses but not multivariate analyses.  
3.5.1 Intracardiac thrombosis in cardiac amyloidosis 
The high incidence of intracardiac thrombosis from Mayo autopsy study confirms the 
observations of Roberts.4 AL type was associated with a 51% incidence compared to only 
16% in the other amyloid groups despite the fact that these groups were older and more 
frequently had AF. Other than case reports and a small autopsy study,10,12,15-17 the Mayo’s 
investigation was the only systemic study to report the high frequency of intracardiac 
thrombosis and clinical thromboembolic complications resulting in mortality. Roberts et al 
retrospectively studied 49 AL and 5 familial type hearts and identified intracardiac thrombi 
in 26%. The clinical implications of these thrombi are unknown. Halligan et al. found 2% of 
biopsy-proven AL patients had clinically documented thromboembolism18 and thrombosis 
was associated increased mortality. Common features of previous reports include middle-
age years of patients, relatively preserved LVEF despite clinical CHF and multiple thrombi. 
A majority of the patients had a poor prognosis. Most patients were in sinus rhythm.  
3.5.2 Intracardiac thrombosis and embolism 
Twenty-six percent of our patients died from embolic complications in the AL group. Not all 
patients with documented embolism had intracardiac thrombosis at autopsy (30%) perhaps 
because some thrombi had been dislodged prior to death. Alternatively, some patients could 
have had other sources for thrombi.  
3.5.3 Clinical variables and thromboembolism 
Several studies show that advanced age, AF, CHF, diabetes, and hypertension are risk 
factors for thromboembolism in non amyloid patients.19,20 In the Mayo autopsy 
investigation, the mean age was younger in patients with thromboembolism. This is because 
primary amyloid patients were much younger than the non primary patients and they were 
8.4 times more likely to develop thromboembolism. Thromboembolic patients also had a 
fewer comorbidities because of their younger age. By multivariate analyses, only two 
clinical variables, AF and AL cardiac amyloidosis, were independently associated with 
thromboembolism. After TTE variables and clinical variables were introduced into the 
analysis, AF was no longer an independent risk factor. This is likely because AF was 
associated with poor atrial mechanical activity and LV diastolic dysfunction. Nonetheless, 
we suggest that when present, AF should be considered a marker of possible intracardiac 
thrombosis, especially in AL patients. On the other hand, higher heart rate at TTE is 
independently associated with increased risk for thromboembolism. Increased heart rate 
reflects the underline severity of disease and therefore indicates decompensation.  
Of interest, the presence of CAD and the severity of CAD at autopsy were negatively 
associated with intracardiac thrombosis and embolic events. This is likely because CAD is 
associated with older age and the mean age in our study was significantly older in the other 
amyloid groups. After adjusting for age, amyloid type, and other variables, CAD was not 
associated with intracardiac thrombosis or embolism.  
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Clinical CHF and NYHA class were not significantly different in patients with or without 
thromboembolism. Multivariate analyses only confirmed an association between poor LV 
diastolic function, i.e., restrictive diastology (class 3 or 4) by TTE and intracardiac thrombosis 
and embolism. Because many patients were elderly with multiple comorbidities, the clinical 
diagnosis of CHF or NYHA class is subjective indicator of over all well being and may not 
be always accurate. TTE with structure and function evaluation (including diastolic measures) 
provides more comprehensive information and is more helpful for risk stratification.  
3.5.4 TTE characters and thromboembolism 
Multivariate analyses showed only LV diastolic function and higher HR at TTE, and to a 
lesser extent, RV wall thickness were significantly associated with thromboembolism. Poor 
atrial mechanical activity (mitral A and a’ velocity) was significant only in univariate 
analyses. The observation was not surprising because LV diastolic function was graded 
based on several echo features including mitral inflow profile and mitral tissue Doppler.  
RV wall thickness is associated with abnormal RV diastolic function.21 Advanced RV 
infiltrate by amyloid (≥7mm) was associated with a restrictive tricuspid inflow filling 
pattern; lesser thickness was associated with abnormal RV relaxation.21 In the current study, 
the mean RV wall thickness was 8.3 mm in the thromboembolic group. A thickened RV wall 
therefore reflected more advanced amyloid deposition with a poor RV diastolic function 
and with consequent stasis and thrombosis.  
The LA volume index and RA size were not significantly different in the patients with and 
without thromboembolism although the indexes were large in both (>40cc/m2). One would 
speculate that atrial size should be bigger in the thromboembolic group because of poor LV 
diastolic function, higher LV/LA filling pressure as estimated by E/e’ and a thicker RV 
wall. In the study, 73% of thromboembolic patients had AL amyloid and thus a worse 
prognosis. It may be that patients with AL amyloidosis do not have time to develop atrial 
enlargement because of short survival times. In addition advanced age and comorbidities 
contribute to increased LA size22 and thromboembolic patients were younger and had a 
fewer comorbidities. Finally, it is possible that amyloid infiltrate in the atria prevented them 
from being distended as suggested by Modesto et al with strain imaging.23  
3.5.5 Mechanism for thromboembolism  
Our TTE data support the concept stasis could lead to intracardiac thrombosis. Even though 
the mean LVEF was relatively-preserved, those with intracardiac thrombosis had lower 
LVEF. Furthermore, the LV diastolic function and atrial mechanical activity were more 
impaired. Reduced atrial contractility secondary to amyloid infiltration has been reported17,24 
and LV diastolic function is typically impaired before systolic function.25 The combination of 
systolic and diastolic ventricular dysfunction, chronic amyloid infiltrate in the atria, and 
direct toxic effect on myocardium26 could lead to atrial mechanical dysfunction, atrial 
enlargement, and blood stasis.23,27 Such atrial electrical-mechanical dissociation may partially 
explain why many cardiac amyloidosis patients developed atrial thrombosis while in sinus 
rhythm.17,24,28 It is possible that endomyocardial damage and endothelial dysfunction from 
amyloid depositions may be responsible.29,30 Hypercoagulability may also contribute.7,31 
3.5.6 Summary of the Mayo autopsy study 
There was a high frequency of intracardiac thrombosis in patients with cardiac amyloidosis, 
especially the AL type, despite sinus rhythm and preserved LVEF. Intracardiac thrombosis 
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leads to embolic events and mortality. The presence of AL type, AF, poor LV diastolic 
function, greater RV wall thickness, and higher heart rare were associated with 
thromboembolism. Poor LV diastolic function and atrial mechanical activity are likely 
contributory to the complication. Transesophageal echocardiography (TEE) may be 
indicated for earlier detection11 in the high risk patients since TTE is well known for its 
insensitivity in detecting intracardiac thrombosis especially in the atria. If intracardiac 
thrombosis is detected, anticoagulation therapy may be indicated. However, anticoagulation 
may exacerbate the hemorrhagic tendency well known in amyloidosis because of fragile 
blood vessel walls secondary to amyloid deposition and the coexisting coagulopathy.2,31 
Three AL amyloid patients in this study died from massive gastrointestinal bleeding.  
4. TEE, intracardiac thrombosis, embolism and anticoagulation therapy in 
patients with cardiac amyloidosis  
The autopsy study have identified a high prevalence of intracardiac thrombosis in these 
patients at autopsy, especially in AL cardiac amyloidosis.4,13 Furthermore, in our autopsy 
series, systemic embolism was a significant cause of mortality.13 However, it is possible that 
autopsy series may over emphasize the frequency of intracardiac thrombosis and there only 
have been a few anecdotal reports in the literature on intracardiac thrombosis detected by 
TEE or TTE in live patients.9-12,15-17 The prevalence of intracardiac thrombus and the effects 
of anticoagulation in living cardiac amyloid patients has not been reported. Accordingly, we 
evaluated both TTE and TEE studies from patients with various types of cardiac 
amyloidosis to determine how frequently detectable intracardiac thrombi are present; the 
clinical and echocardiographic characteristics associated with their presence; and the effects 
of therapeutic anticoagulation.  
4.1 Study groups 
We searched the Mayo Clinic Hematology Data base for all cases of amyloidosis from 1999 
to 2007. There were 156 patients had cardiac amyloid who also had TEE. The detail of 
exclusion and inclusion criteria was reported elsewhere.32  
Clinical information, including demographic data, comorbidities, presence of heart failure 
(HF), New York Heart Association (NYHA) functional class, the use of anticoagulants prior 
and at the time of TEE, ECG, TTE, TEE, MRI and other laboratory data were abstracted from 
clinical records. Cardiac rhythm was determined from the patient’s ECG, Holter monitoring 
data, and medical records. INR and APTT around the time of TEE were charted. 
Therapeutic anticoagulation was defined as INR ≥ 2 at the time of TEE or documented two 
or more consecutive therapeutic INR 2-3 prior to TEE for those with long term 
anticoagulation, or at least 48 hours of intravenous heparin therapy or 48 hours of 
subcutaneous low molecular weight heparin therapy prior to TEE. Other abstracted 
information included results of tissue biopsies, urine and serum protein electrophoresis, 
immunofixation, serum free light chain assay, genetic testing, and family history.13 
4.2 Echocardiograms 
TTE and TEE studies were reviewed independently without knowledge of the clinical and 
pathological data and was reported previously13 The TEE studies were reviewed for 
presence or absence of intracardiac thrombus and their location and size.14 Left atrial 
appendage (LAA) and LA spontaneous contrast and their severity were semi-quantified as 
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none, mild, moderate or severe (0, 1, 2, or 3 respectively).33 Left atrial appendage emptying 
velocity was measured by pulse Doppler echocardiography as previously reported.33 The 
degree of atherosclerosis in aorta was semi-quantified as none, mild, moderate or severe.34 35 
HR and BP at the time of TEE were documented.  
4.3 Demographic data and amyloid subtypes  
Amyloidosis was AL type in 80, 56 wild TTR type, 17 mutant TTR type, and 3 AA type 
(Table 6). Because AA are rare, they were combined into one group with the wild and 
mutant TTR cases (called other amyloidosis, n=76). Compared with other amyloid group, 
the AL group was younger; had fewer males, less AF, was less often receiving 
anticoagulation therapy and less often had a history of hypertension, and were more likely 
to be treated with stem cell transplantation, all p ≤ 0.05 (Table 6). There was no significant 
difference in a history of HF, NYHA class or other variables between the two groups listed 
in Table 1 (all p>0.05). 
 
 All Patients 
(n=156) 
AL 
(n=80) 
Other Amyloid 
(n=76) 
P value 
Age, years 67 ± 11 61 ± 10 74 ± 9 <0.0001 
Gender, % male 77 65 89 0.0003 
Body mass index, kg/m2 26.1 ± 4.4 26.4±4.2 25.6±4.7 0.35 
Heart Rate, bpm 81 ± 18 81 ± 19 80 ± 16 0.51 
Systolic BP, mm Hg 118 ± 22 117±21 120±22 0.29 
Diastolic BP, mm Hg 70 ± 14  71±13 69±14 0.34 
Atrial fibrillation, % 64 56 72 0.03 
Anticoagulation, % 43 33 54 0.007 
Hypertension, % 39 30 49 0.02 
Diabetes, % 5 4 7 0.43 
NYHA class 1, % 21 20 22 
NYHA class 2, % 35 34 36 
NYHA class 3, % 37 39 34 
NYHA class 4, % 8 9 8 
0.95 
Median NYHA class  2 (1-3) 2 (1-3) 2 (1-3) 0.64 
Syncope, % 24 21 26 0.46 
Stem cell transplant, % 11 21 0 <0.0001 
History of 
thromboembolism,%  
22 24 21 0.69 
Table 6. Patient characteristics in AL and the other amyloid groups in TEE study 
4.4 Indications for TEE 
TEE was performed in 57 patients (37%) for AF and/or prior to direct current cardioversion, 
in 33 patients (21%) searching for source for embolism, in 14 patients (9%) for evaluation of 
valvular heart disease, in 12 patients (8%) for rule out endocarditis, and in 6 patients (4%) 
for other reasons. TEE was performed prospectively in 34 cardiac amyloid patients (22%) 
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after our initial autopsy observations at the discretion of referral hematologists or 
cardiologists. All TEE studies were performed without major complications or mortality. All 
patients with TEE also had TTE studies with exception in one.  
4.5 Intracardiac thrombus  
There were 58 intracardiac thrombi identified in 42 (27%) of 156 patients by TEE. Most 
patients with thrombi (30 patients, 71%) had 1 thrombus while 8 patients (19%) had 2 
thrombi, and 4 patients (10%) had 3. Most clots occurred in the left atrium/appendage 
(n=32) or in the right atrium/appendage (n=19). Of all of these thrombi detected by TEE, 
only 3 were detected by TTE. There was a significant difference in the frequency of 
intracardiac thrombosis between patients with AL amyloidosis and the other types (35% vs. 
18%, p=0.02). The frequencies for intracardiac thrombosis were 18% for wild TTR type, 17% 
for mutant TTR type, and 33% for AA type.  
The frequency of intracardiac thrombi in those receiving therapeutic anticoagulants was 
only 13%, much lower than in those not on therapeutic anticoagulant therapy at the time of 
TEE studies (37%, p=0.001). We further analyzed these patients on chronic anticoagulation 
with therapeutic INR at the time of TEE with stratifying findings according to persistent or 
permanent AF versus non AF. Chronic anticoagulation was associated with a significantly 
lower risk for intracardiac thrombosis [prevalence 18 % (6/33) versus 50 % (13/26) in those 
who were not on anticoagulation, p=0.01]. Similar trend was observed for patients who had 
no AF with respective intracardiac thrombosis prevalence 0 % (0/12) in chronic 
anticoagulation group versus 20 % (8/40) in the no anticoagulation group, p=0.09. 
4.6 Clinical characteristics and thrombosis  
Compared to the group without thrombosis, the intracardiac thrombosis group was 
younger, had more AF but was less apt to be receiving therapeutic anticoagulation (table 
7). They were also more likely to have AL amyloidosis, had a lower systolic BP and faster 
heart rate, all p ≤ 0.05. Similar results were obtained after the exclusion of patients who 
had AF. The prevalences of intracardiac thrombosis were 0% (0/21) in other types of 
cardiac amyloid patients who had no AF; 23% (8/35) in those with AL amyloidosis who 
had no AF, 25% (14/55) in other types with AF; and 44% (20/45) in AL patients with AF, 
p=0.0002. Other demographic and clinical variables were similar. Interestingly, the group 
with thrombosis did not have more frequent documented history of embolism. 
Furthermore, there was no significant difference in prevalence of intracardiac thrombosis 
between those patients studied retrospectively and those studied prospectively (31% vs. 
25%, p=0.25).  
4.7 TTE and thrombosis (table 8) 
The group with thrombi had a smaller LV end diastolic dimension, a thicker LV posterior 
wall, a larger RA size, a smaller SV and CI, a lower LVEF, worse LV diastolic function, a 
shorter deceleration time, poorer LA mechanical activity (a lower A and a’ velocity), and a 
higher E/A and E/e’ than the non thrombotic group. Furthermore, PV peak systolic velocity 
and A velocity were significantly lower and D/S was higher (all p ≤ 0.05). LA volume index 
was not statistically different. After exclusion of AF patients, the differences of several TTE 
parameters between the thrombosis group and the non thrombosis group were no longer 
statistically different although the trends were similar (table 8).  
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 All Patients Patients without AF 
Thrombus status All  
(n=156) 
With 
(n=42) 
Without 
(n=114) 
P 
value 
With  
(n=8)  
Without 
(n=48) 
P 
value 
Age, years 67 ± 11 64 ± 12 69 ± 11 0.02 56 ± 9 65±12 0.04 
Gender, % male 77 64 82 0.06 50 63 0.23 
Body mass index, kg/m2 26.1 ± 4.4 25.2±4.7 26.4±4.3 0.18 24.5±2.9 25.6±3.9 0.55 
Hypertension, % 39 26 43 0.06 13 41 0.12 
Diabetes, % 5 2 6 0.35 0 7 0.53 
CHF, % 79 88 75 0.36 88 62 0.46 
NYHA class 1, % 21 12 25 12 38 
NYHA class 2, % 35 36 34 25 27 
NYHA class 3, % 37 43 34 50 29 
NYHA class 4, % 8 9 7 
0.36 
13 6 
0.46 
Median NYHA class  2 (1-3) 3 (1-4) 2 (1-3) 0.10 3 (1-4) 2 (1-3) 0.11 
Atrial fibrillation, % 64 81 58 0.008 0 0 -- 
Anticoagulation, % 43 21 51 0.001 0 29 0.05 
Syncope, % 24 29 22 0.39 27 14 0.18 
AL amyloidosis, %  51 67 46 0.02 100 56 0.01 
Stem cell transplant, % 11 12 11 0.93 14 20 0.62 
History of 
thromboembolism, % 
22 24 22 0.92 32 30 1.00 
Nephrotic Syndrome, % 17 24 15 0.23 25 27 0.90 
Systolic BP, mm Hg 118 ± 22 110 ± 20 122 ± 22 0.002 91 ± 7 122 ± 21 0.0001 
Diastolic BP, mm Hg 70 ± 14 68±13 71±14 0.18 57±10 71±15 0.02 
Heart Rate, bpm 81 ± 18 86 ± 16 79 ± 18 0.01 87±14 78±14 0.13 
Table 7. Characteristics in patients with and without Intracardiac Thrombosis in TEE study 
4.8 TEE and thrombosis (table 9) 
Those with intracardiac thrombi more frequently had spontaneous echo contrast in the LA, 
and also more severe spontaneous echo contrast in both the LA and LAA and, lower LAA 
emptying velocity compared to the non thrombotic group. There is no difference in the 
degree of atherosclerosis in aorta. Similar results were obtained after the exclusion of 
patients who had AF. 
4.9 Multivariate analysis and ROC (table 10) 
By multivariate analysis, AF, therapeutic anticoagulation, and lower systolic BP were 
independently associated with intracardiac thrombosis while there was a borderline trend 
for AL type in the model when only clinical variables were used. For TTE variables, LV 
diastolic function was the only variable independently associated with intracardiac 
thrombosis. Comparing restrictive filling with non restrictive filling LV diastolic function, 
the OR is 10.6 with 95% CI 1.5-220.3, p=0.04. For TEE variables, the only independent 
variable associated with intracardiac thrombosis was LAA emptying velocity. When clinical, 
TTE and TEE variables which were statistically significant by the above 3 models were 
included in the final model, AF, anticoagulation therapy, LV diastolic function, and LAA 
emptying velocity were independently associated with intracardiac thrombosis.  
The receiver operating characteristic analysis for LAA emptying velocity to predict 
intracardiac thrombosis is performed. Using 15 cm/s as the cut off, LAA emptying velocity 
had a sensitivity of 70% and a specificity of 73%. By using 23 cm/s as the cut off, which is 
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 All Patients Patients without AF 
Thrombus Status  With 
(n=42) 
Without 
(n=114) 
P value With  
(n=8) 
Without 
(n=48) 
P value 
LV end diastolic diameter, 
mm 
45±8 43±8 46±7 0.02 44±9 45±8 0.77 
LV end systolic diameter, 
mm 
32±8 33±10 32±8 0.55 37±10 30±9 0.09 
LV septal thickness, mm 15.7±3.9 16.3±3.6 15.3±3.9 0.20 15±3.7 14.9±3.6 0.95 
LV posterior wall 
thickness, mm 
14.8±3.3 15.8±3.2 14.4±3.2 0.02 14.4±3.1 13.9±3.1 0.67 
RV free wall thickness, 
mm 
8.8±2.5 9.5±2.9 8.5±2.3 0.08 9.8±2.3 8.6±2.5 0.33 
LA volume index, ml/m2) 48±22 51±17 47±23 0.38 43±7 41±29 0.90 
RA enlargement (0-3) 2 (0-3) 3 (1-3) 2 (0-3) 0.008 2 (1-3) 1 (0-3) 0.10 
Normal RA, % 15 5 19 0 40 
Mild RAE, % 14 7 16 29 18 
Moderate RAE, % 26 29 25 29 12 
Severe RAE, % 45 59 40 
0.04 
42 30 
0.20 
Stroke volume, mL 65±23 51±18 71±23 0.0009 40±11 73±26 0.001 
CI, L/m2/min 2.6±0.8 2.3±0.6 2.8±0.9 0.0002 1.9±0.5 2.9±1.0 0.008 
LVEF, % 50.9±14.9 43.2±13.7 53.8±14.4 0.0001 37.8±15 56±15 0.002 
Median LV diastolic 
function 
3 (1-4) 3 (3-4) 2 (1-3) 0.0001 4 (3-4) 2(1-3) 0.0002 
Normal LV diastolic 
function, % 
1 0 1 0 2 
LV diastolic function 1, % 14 0 18 0 35 
LV diastolic function 2, % 31 8 39 0 35 
LV diastolic function 3, % 43 59 38 43 26 
LV diastolic function 4, % 11 33 4 
0.0001 
57 2 
0.0001 
Mitral deceleration time, 
ms 
181±54 159±39 188±56 0.004 144±24 195±65 0.09 
Mitral E velocity, m/s 0.94±0.29 0.93±0.26 0.94±0.31 0.85 0.90±0.24 0.96±0.33 0.70 
Mitral A velocity, m/s 0.44±0.33 0.21±0.18 0.52±0.33 0.0001 0.28±0.10 0.64±0.35 0.0003 
E/A 2.7±1.9 3.9±2.2 2.3±1.6 0.001 5.0±3.0 2.1±1.9 0.004 
Mitral annulus s’ velocity, 
cm/s 
4.6±1.8 3.7±1.8 4.9±1.7 0.008 3.0±1.0 5.3±1.6 0.01 
Mitral annulus e’ velocity, 
cm/s 
4.5±1.8 3.6±1.4 4.8±1.9 0.002 3.5±1.0 5.0±2.0 0.09 
Mitral annulus a’ velocity, 
cm/s 
3.0±2.6 1.8±2.1 3.6±2.9 0.01 2.0±1.0 4.6±3.1 0.11 
E/e’ 23±12 29±15 21±10 0.002 27±13 21±11 0.21 
PV systolic velocity, m/s 0.35±0.18 0.28±0.18 0.38±0.18 0.009 0.22±0.11 0.46±0.18 0.007 
PV diastolic velocity, m/s 0.62±0.20 0.64±0.18 0.61±0.20 0.45 0.67±0.23 0.55±0.22 0.23 
PV A velocity, m/s 0.21±0.14 0.13±0.11 0.23±0.14 0.004 0.10±0.12 0.27±0.16 0.03 
PV diastolic/systolic ratio 2.4±1.8 3.0±1.7 2.2±1.8 0.05 3.1±0.7 1.5±1.2 0.008 
RV systolic pressure, mm 
Hg 
42.7±12.3 44.4±11.6 42.1±12.6 0.33 40±9 41±14 0.89 
Table 8. TTE characteristics in patients with and without intracardiac thrombosis 
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comparable as reported previously,33 the sensitivity increased to 100% but specificity 
decreased to 53%. The area under curve was 0.81. Using grade 3 as a cut off value for LV 
diastolic function, it had a sensitivity of 92% and a specificity of 59%. The area under curve 
was 0.82.  
No significant differences existed in intracardiac thrombosis between LV diastolic function 
grade 2 and grade 1 [0% (0/21) vs. 7% (3/46), p=0.49]. The prevalence of intracardiac 
thrombosis was 44% for grade 3 or 4. Comparing restrictive filling pattern (grade 3 or 4 
diastolic function) with non restrictive filling pattern (grade 1 or 2), the OR for intracardiac 
thrombosis is 17.1 with 95% CI 5.9-73.8, p<0.0001, by univariate analysis. 
 
 All Patients Patients without AF 
Thrombus Status All 
(n=156)  
With 
(n=42) 
Without 
(n=114) 
P value With 
(n=8) 
Without 
(n=48) 
P 
value 
LAA emptying velocity, cm/s 23 ± 14 13 ± 5 27 ± 15 0.0001 11±2 35±17 0.03 
LAA spontaneous contrast (%) 61 92 50 0.0001 100 30 0.004 
No LAA spontaneous contrast (%) 39 8 50 0 71 
LAA spontaneous contrast 1 (%) 8 0 11 0 11 
LAA spontaneous contrast 2 (%) 17 14 18 0 9 
LAA spontaneous contrast 3 (%) 36 78 22 
0.0001 
100 9 
0.0001 
Medium LAA spontaneous contrast 2 (0-3) 3 (1-3) 1 (0-3) 0.0001 3 (3-3) 0 (0-2) 0.0001 
No LA spontaneous contrast (%) 39 8 50 0 73 
LA spontaneous contrast 1 (%) 9 0 13 0 9 
LA spontaneous contrast 2 (%) 29 46 23 40 11 
LA spontaneous contrast 3 (%) 23 46 14 
0.0001 
60 7 
0.001 
Medium LA spontaneous contrast 2 (0-3) 2 (2-3) 0 (0-2) 0.0001 2 (2-3) 0 (0-2) 0.0001 
Atherosclerosis (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 0.63 1 (0-1) 1 (0-2) 0.96 
Table 9. TEE characteristics in subjects with and without intracardiac thrombosis 
 
Dependent Variate Models * Predictors OR 95 % CI P value 
Thrombosis Model 1 AL type 2.3 0.96-5.6 0.06 
  AF 6.8 2.5-20.7 0.0001 
  Anticoagulation 0.2 0.07-0.47 0.0003 
  SBP 0.7 0.55-0.87 0.0008 
 Model 2 LV diastolic function@ 10.6 1.5-220.3 0.04 
 Model 3 LAA emptying velocity$ 0.2 0.05-0.57 0.002 
 Model 4 AF 11.8 1.0-395.2 0.05 
  Anticoagulation 0.09 0.01-0.51 0.006 
  LV diastolic function@ 15.2 7.5->999.9 0.008 
  LAA emptying velocity$ 0.1 0.01-0.32 0.0001 
* Model 1: Clinical variates included are amyloid type, AF, anticoagulation, HR and SBP (with 10 mmHg 
increase).  
Model 2: TTE variables included are LV diastolic function (@: grade 3 or 4 versus grade 2 or less), LVEF, 
SV, and mitral A velocity.  
Model 3: TEE variables included are LAA emptying velocity ($: increase in 10cm/s in velocity), 
spontaneous echo contrast in LA and LAA (semi-quantification as 0-3).  
Model 4: Combined model included amyloid type, AF, anticoagulation, SBP, LV diastolic function, and 
LAA emptying velocity. 
Table 10. Predictors for thromboembolism by multivariate analyses 
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Multivariate analysis with AF, LAA emptying velocity, and LV diastolic function as 
dependent variables increased area under curve to 0.85. When further stratifying thrombosis 
risk based on LAA emptying velocity and LV diastolic function, we found 0% intracardiac 
thrombosis in patients with LAA emptying velocity > 15 cm/s and LV diastolic function 
grade ≤ 2, 26 % in patients with either LAA emptying velocity ≤ 15 cm/s or LV diastolic 
grade 3 or 4, and 67% in patients who had both (p<0.0001). Similar results were obtained 
after further stratification by AF. The respective prevalence of intracardiac thrombosis was 
0%, 15%, and 50% for non AF patients (p=0.02), and 0%, 32%, and 72% for AF patients 
(p=0.002). 
4.10 Clinical implications of TEE study 
Our data from a large TEE study of patients with different types of cardiac amyloidosis 
confirms our previous autopsy study describing a high frequency of intracardiac 
thrombosis. We were able to identify that AF, poor LV diastolic function, and LA 
mechanical dysfunction as indicated by a low LAA emptying velocity were independent 
predictors of intracardiac thrombosis. Furthermore, it appears from our data that 
therapeutic anticoagulation therapy protects against intracardiac thrombosis. Low systolic 
blood pressure also was independently associated with increased risk for intracardiac 
thrombosis while AL type cardiac amyloidosis had a borderline trend when only clinical 
variables were considered for multivariates analyses.  
4.11 Intracardiac thrombosis in cardiac amyloidosis 
Our TEE study confirms the observations of Roberts and our prior autopsy study which 
showed a high prevalence of intracardiac thrombosis in cardiac amyloidosis.4 AL type was 
associated with a 35% prevalence of intracardiac thrombosis compared to 18% in the other 
amyloid groups despite the fact that the other amyloid groups were older and more 
frequently had AF. The prevalence of intracardiac thrombosis in TTR related amyloid (either 
wild or mutant TTR) is comparable to that reported in the AF population without 
anticoagulation.36-38 In comparison, AL patients have a higher prevalence of intracardiac 
thrombosis than that reported in the general non amyloid AF population.36-38 In fact, the 
prevalence of intracardiac thrombosis is comparable to that reported in patients with severe 
mitral valve stenosis with AF, which had the highest prevalence of intracardiac thrombosis 
(33%).39  
4.12 Clinical variables and intracardiac thrombosis 
In our current study, AF and low systolic BP were independently associated with 
thrombosis. A low SBP may reflect a low cardiac out put status and severe amyloid heart 
disease with cardiac decompensation. Most importantly, we identified that therapeutic 
anticoagulation was significantly associated with a decreased risk for intracardiac 
thrombosis by both univariate and multivariate analyses.  
Clinical HF and NYHA class were not significantly different in patients with or without 
thrombosis as observed in the Mayo autopsy study.13 Because many patients were elderly 
with multiple comorbidities, the clinical diagnosis of HF or NYHA class is a subjective 
indicator of over all well being and may not be always accurate for grading the severity of 
heart failure. Moreover, other traditional risk factors for thromboembolism such as age, 
diabetes and hypertension were not significantly associated with intracardiac thrombosis. 
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We speculated that risk factors with only modest effect could not be detected in this special 
study population, in which overwhelming effects from AL type, AF, and anticoagulation 
therapy are likely to have masked their modest effects.  
4.13 TTE, TEE characters and intracardiac thrombosis 
Univariate analysis showed that the group with thrombi had evidence of more advanced 
cardiac amyloid deposition as indicated by a smaller LV end diastolic dimension, a thicker 
LV wall, and also poorer LV systolic and diastolic function, a higher LV filling pressure 
estimated by E/e’ as well as less LA mechanical activity than the group without thrombi. 
Furthermore, LA and LAA spontaneous contrast were more often present and more 
pronounced in those with intracardiac thrombi. Similar TTE and TEE results were obtained 
after exclusion of AF patients. Therefore, AF only plays a partial role for intracardiac 
thrombosis. Multivariate analyses showed that the only two echo variable: i.e. LV diastolic 
dysfunction and low LAA emptying velocity, in addition to AF, were independently 
associated with intracardiac thrombosis. The Mayo autopsy and TEE studies and prior 
study support the hypothesis that the combination of systolic and diastolic ventricular 
dysfunction and chronic amyloid infiltrate in the atria lead to atrial mechanical 
dysfunction,17,24 atrial enlargement, and blood stasis.23,27 Such atrial electrical-mechanical 
dissociation at least partially explains why some cardiac amyloid patients developed atrial 
thrombosis while in sinus rhythm.17, 24, 28  
4.14 Anticoagulation and intracardiac thrombosis 
We identified that therapeutic anticoagulation therapy at the time of TEE was associated 
with a significant lower risk for intracardiac thrombosis. Thus, effective anticoagulation 
might reduce thromboembolism, which is a significant contributor for mortality in cardiac 
amyloid patients.13 However, anticoagulation may exacerbate the hemorrhagic tendency, 
which is a well known complication of amyloidosis because of fragile blood vessel walls 
secondary to amyloid deposition and the coexisting coagulopathy in such patients.2,31 In our 
prior autopsy series, three cardiac amyloid patients died from massive gastrointestinal 
bleeding.13 Therefore, the potential benefits of anticoagulation must be carefully weighed 
against possible hemorrhagic complications before anticoagulation is initiated.  
5. Further directions  
A recent study suggests that chemotherapy in AL patients with cardiac involvement results 
in a clinical improvement despite an unchanged TTE appearance.40 Improvement may be 
due to the abolition of the production of new light chains, which are toxic to myocardium 
by increasing oxidant stress and causing diastolic dysfunction.26,41 Furthermore, there has 
been report of echocardiographic improvement and decreased amyloid accumulation by 
99m Tc-PYP scintigram after chemotherapy and stem cell transplant.42 Therefore, it is 
possible that early detection of amyloidosis, vigilant screening for intracardiac thrombosis 
with early anticoagulation, and more aggressive treatment of the underlying plasma 
dyscrasia might improve the prognosis. 3,23,43,44 Because of retrospective study design and 
limited number of patients on anticoagulation, we could not evaluate whether 
anticoagulation will prevent thromboembolism. Further prospective study is needed to 
specifically answer this question.  
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6. Summary 
We demonstrated a high frequency of intracardiac thrombosis in patients with cardiac 
amyloidosis from both autopsy study and from TEE study. The risk for intracardiac 
thrombosis and thromboembolism is especially high in patients who had the AL type, 
presented with AF, had poor LV diastolic function, and poor atrial mechanical function 
were independently associated with increased risk. Importantly, therapeutic anticoagulation 
therapy appeared protective against intracardiac thrombosis. Early screening for 
intracardiac thrombosis by TEE, especially in the high risk patient as identified in our 
studies, may be indicated. If intracardiac thrombosis or severe LAA mechanical dysfunction 
(especially with coexisting restrictive LV filling) is detected, anticoagulation should be 
carefully considered. 
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